Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Nuvectis Pharma (NVCT) Shares Outstanding (Weighted Average) (2021 - 2026)

Nuvectis Pharma has reported Shares Outstanding (Weighted Average) over the past 6 years, most recently at $26.4 million for Q1 2026.

  • Quarterly results put Shares Outstanding (Weighted Average) at $26.4 million for Q1 2026, up 32.64% from a year ago — trailing twelve months through Mar 2026 was $26.4 million (up 32.64% YoY), and the annual figure for FY2025 was $21.8 million, up 27.46%.
  • Shares Outstanding (Weighted Average) reached $26.4 million in Q1 2026 per NVCT's latest filing, up from $21.8 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $26.4 million in Q1 2026 and bottomed at $9.2 million in Q1 2022.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $16.7 million (2024), compared with a mean of $16.8 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) surged 196.55% in 2022 before it increased 6.99% in 2024.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $12.7 million in 2022, then rose by 22.9% to $15.6 million in 2023, then grew by 10.01% to $17.1 million in 2024, then rose by 27.46% to $21.8 million in 2025, then rose by 21.24% to $26.4 million in 2026.
  • Business Quant data shows Shares Outstanding (Weighted Average) for NVCT at $26.4 million in Q1 2026, $21.8 million in Q4 2025, and $21.4 million in Q3 2025.